Dr. Richon is a scientifically trained executive with decades of leadership experience in small biotechnology companies, global pharmaceutical companies, and academia. Before joining Ribon, Dr. Richon was the Vice President and Global Head of Oncology Research and Translational Medicine at Sanofi where she led the company’s early oncology efforts.
Prior to Sanofi, Dr. Richon was Vice President of Biological Sciences at Epizyme, Inc., a biotechnology company pioneering therapeutics based upon epigenetics. Earlier in her career, she was Founder and Executive Director of Aton Pharmaceuticals, which was acquired by Merck in 2004. Aton was formed to develop HDAC inhibitors, including vorinostat, an HDAC inhibitor that Dr. Richon developed during her tenure at Sloan-Kettering Cancer Center and vorinostat was the first HDAC inhibitor approved by the FDA while she was at Merck.
Dr. Richon received her Ph.D. in Biochemistry at the University of Nebraska Medical Center and a B.A. in Chemistry at the University of Vermont.